Condition: Lichen Planus · Sponsor: Institut Pasteur
Lichen planus (LP) is a chronic inflammatory disease of unknown aetiology, affecting the skin and mucous membranes, characterised by a CD8+ cytotoxic T-cell infiltrate, associated with epithelial cell death and disruption of the basement membrane zone. In previous work, T cell antigen receptor (TCR) repertoire studies were performed. In all patients tested, whether with erosive or non-erosive LP, unique nucleotide sequences, called clonotypes, have been identified. They appear during the process of TCR gene rearrangement. These clonotypes are specific for human papillomavirus (HPV) in blood and lesions, suggesting antigenic stimulation of these clonotypes by a viral epitope of HPV, which crosses with an epitope on keratinocytes. The diagnosis of LP is made on the basis of clinical and histological criteria, but in some patients and in some anatomical locations, the diagnosis is difficult to make and LP may be confused with other skin conditions.
This description comes directly from the study's public registry record.
Marie-Lise Gougeon · 1 40 66 97 87 · marie-lise.gougeon@pasteur.fr
Sandrine Fernandes Pellerin · 1 45 68 81 79 · sandrine.fernandes-pellerin@pasteur.fr
Always discuss trial participation with your own doctor first.
| CHU de Besançon | Besançon, France | Recruiting |
| CHU Paris Seine-Saint-Denis- Hôpital Avicenne | Bobigny, France | Recruiting |
| Centre Medical de l'Institut Pasteur | Paris, France | Recruiting |
| Hôpital Saint-Louis | Paris, France | Recruiting |
| Hôpital Robert Debré, CHU de Reims | Reims, France | Recruiting |
| CHU de Rouen | Rouen, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06451744